Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 6;23(9):5217.
doi: 10.3390/ijms23095217.

Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy

Mattia Barbot  1 , Alessandro Mondin  1 , Daniela Regazzo  1 , Valentina Guarnotta  2 , Daniela Basso  3 , Carla Giordano  2 , Carla Scaroni  1 , Filippo Ceccato  1
Affiliations

Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy

Mattia Barbot et al. Int J Mol Sci. .

Abstract

Cushing’s disease (CD) causes diabetes mellitus (DM) through different mechanisms in a significant proportion of patients. Glucose metabolism has rarely been assessed with appropriate testing in CD; we aimed to evaluate hormonal response to a mixed meal tolerance test (MMTT) in CD patients and analyzed the effect of pasireotide (PAS) on glucose homeostasis. To assess gastro-entero-pancreatic hormones response in diabetic (DM+) and non-diabetic (DM−) patients, 26 patients with CD underwent an MMTT. Ten patients were submitted to a second MMTT after two months of PAS 600 µg twice daily. The DM+ group had significantly higher BMI, waist circumference, glycemia, HbA1c, ACTH levels and insulin resistance indexes than DM− (p < 0.05). Moreover, DM+ patients exhibited increased C-peptide (p = 0.004) and glucose area under the curve (AUC) (p = 0.021) during MMTT, with a blunted insulinotropic peptide (GIP) response (p = 0.035). Glucagon levels were similar in both groups, showing a quick rise after meals. No difference in estimated insulin secretion and insulin:glucagon ratio was found. After two months, PAS induced an increase in both fasting glycemia and HbA1c compared to baseline (p < 0.05). However, this glucose trend after meal did not worsen despite the blunted insulin and C-peptide response to MMTT. After PAS treatment, patients exhibited reduced insulin secretion (p = 0.005) and resistance (p = 0.007) indexes. Conversely, glucagon did not change with a consequent impairment of insulin:glucagon ratio (p = 0.009). No significant differences were observed in incretins basal and meal-induced levels. Insulin resistance confirmed its pivotal role in glucocorticoid-induced DM. A blunted GIP response to MMTT in the DM+ group might suggest a potential inhibitory role of hypercortisolism on enteropancreatic axis. As expected, PAS reduced insulin secretion but also induced an improvement in insulin sensitivity as a result of cortisol reduction. No differences in incretin response to MMTT were recorded during PAS therapy. The discrepancy between insulin and glucagon trends while on PAS may be an important pathophysiological mechanism in this iatrogenic DM; hence restoring insulin:glucagon ratio by either enhancing insulin secretion or reducing glucagon tone can be a potential therapeutic target.

Keywords: Cushing’s disease; diabetes mellitus; incretin; mixed meal test tolerance test; pasireotide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Glycemia, insulin, C-peptide and glucagon AUC after MMTT. Solid line, DM+ patients; dashed line, DM− patients. * p value < 0.05.
Figure 2
Figure 2
GIP, GLP-1, ACTH and cortisol AUC after MMTT. Solid line, DM+ patients; dashed line, DM− patients. * p value < 0.05.
Figure 3
Figure 3
Glycemia, insulin, C-peptide and glucagon AUC after the meal. Dashed line represents pre-treatment values whereas solid line the post-treatment curve. * p value < 0.05.
Figure 4
Figure 4
GIP, GLP-1, ACTH and cortisol AUC after the meal. Dashed line represents pre-treatment values whereas solid line the post-treatment curve.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Barbot M., Ceccato F., Scaroni C. Diabetes Mellitus Secondary to Cushing’s Disease. Front. Endocrinol. 2018;9:284. doi: 10.3389/fendo.2018.00284. - DOI - PMC - PubMed
    1. Scaroni C., Zilio M., Foti M., Boscaro M. Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management. Endocr. Rev. 2017;38:189–219. doi: 10.1210/er.2016-1105. - DOI - PubMed
    1. Giordano C., Guarnotta V., Pivonello R., Amato M.C., Simeoli C., Ciresi A., Cozzolino A., Colao A. Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur. J. Endocrinol. 2014;170:311–319. doi: 10.1530/EJE-13-0754. - DOI - PubMed
    1. American Diabetes Association Classification and diagnosis of diabetes: Standards of medical care in diabetes. Diabetes Care. 2020;43((Suppl. S1)):S14–S31. doi: 10.2337/dc20-s002. - DOI - PubMed
    1. Eriksen M., Jensen D.H., Tribler S., Holst J.J., Madsbad S., Krarup T. Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. Diabetologia. 2015;58:920–928. doi: 10.1007/s00125-015-3522-y. - DOI - PubMed